Sage Journals: Discover world-class research

Abstract

Background

The management of unruptured intracranial aneurysms (UIA) requires a balance between procedural risks and the potential benefit of rupture prevention.

Objective

The aim of this study is to evaluate the clinical and anatomical results of endovascular treatment for UIAs at our institution, to benchmark our practice and potential areas for improvement, and enable transparent communication with patients by providing accurate, evidence-based information.

Methods

We reviewed all patients treated for an UIA between January 2017 and July 2022. Patients were grouped according to treatment technique: simple or balloon-assisted coiling; stent-assisted coiling; or flow-diverter stent placement. Clinical outcomes included perioperative mortality, transient (<3 months), and permanent morbidity (>3 months). Anatomical results were graded with the Raymond-Roy or the O’Kelly-Marotta scales. Retreatment rates, length of hospitalization, readmissions, irradiation time, and total radiation dose were assessed.

Results

In total, 169 patients with 201 UIAs underwent 187 endovascular procedures without death, 1% permanent morbidity, 8% transient morbidity, and 4% retreatment. The treatment subgroups analysis shows an absence of permanent morbidity associated with flow-diverter stenting and stent-assisted coiling. Simple/balloon-assisted coiling suffered 2.6% permanent morbidity. Transient morbidity was observed in 9%, 9.5%, and 6.6% of flow-diverter stenting, stent-assisted coiling, and simple/balloon-assisted coiling, respectively.

Conclusions

In our hospital, about one in a hundred procedures caused lasting problems, while about one in 25 aneurysms needed a second treatment. These results reflect our case selection and multidisciplinary approach. Reporting them transparently helps patients understand what outcomes to expect at our hospital.

Keywords

Endovascular treatment outcomes patient informed decision-making unruptured intracranial aneurysm

Introduction

Unruptured intracranial aneurysms (UIAs) pose a complex therapeutic challenge, balancing procedural risk with rupture prevention.^1,2 Endovascular treatment has become a cornerstone in constant evolution,^3,4 yet clinical and anatomical results vary based on case complexity and technique.

The objective of this study was to assess how UIAs were treated endovascularly at our center, to understand our outcomes in the context of the literature, and to provide patients with realistic, local data to support treatment decisions.

Methods

We conducted a retrospective analysis of our institution's prospectively maintained database to review all consecutive patients who underwent endovascular treatment for UIAs between January 2017 and July 2022. This period marks the establishment of our interventional neuroradiology team. The goal was to assess clinical and anatomical outcomes in our patient cohort. To assess outcomes based on the technical complexity of the endovascular treatment, we categorized the patient cohort into three groups: treated with (1) flow-diverter stent; (2) stent-assisted coiling; and (3) simple- or balloon-assisted coiling. Treatment modality was not randomized but decided in a multidisciplinary board, based mainly on aneurysm location and shape (aspect ratio). Complex MCA aneurysms were usually referred for clipping, while carotid and posterior circulation aneurysms were more often treated endovascularly.⁵

Clinical outcomes included perioperative mortality and morbidity. Morbidity was classified as transient when neurological symptoms, deficits or procedure-related complications resolved within 3 months, and as permanent when they persisted beyond this period. Functional status was systematically assessed using the disability modified Rankin Scale (mRS) ranging from 0 (no symptoms) to 6 (death).

Anatomical outcomes included: aneurysm occlusion rates determined using the Raymond-Roy classification⁶ with grade 1 meaning a completely sealed aneurysm and grade 3 a remaining aneurysm filling after coiling, and the O’Kelly-Marotta scale⁷ for those treated with FD stents, with class D corresponding to complete occlusion of the aneurysm. Additionally, we analyzed hospitalization duration, readmission, and retreatment rates, as well as procedural factors, such as irradiation time and total radiation dose delivered to the patient. This study assessing the quality of procedures and outcomes retrospectively was deemed to fall outside the scope of Swiss human research legislation and consequently did not require approval by a local ethics committee. The study protocol was registered prior before starting the study.

Statistical analysis

Descriptive statistical analyses were performed to summarize the variables under investigation. Continuous variables were reported as mean and standard deviation (mean ± SD). Discrete variables as median and interquartile range (median,[IQR]). Additionally, percentiles were calculated to illustrate the proportion of specific categories within the total sample. Proportions are reported with 95% confidence intervals calculated using the Wilson score method (%, [95%CI].

Results

Between January 2017 and July 2022, a total of 465 patients with 497 intracranial aneurysms were treated at our center. Of these, 315 aneurysms underwent endovascular treatment, while 182 underwent surgical intervention. Among the aneurysms treated with endovascular treatment, 201 were unruptured and 114 were ruptured. Almost all unruptured middle cerebral artery aneurysms were treated surgically (90/92, 97.8%, [94.8–100%]), most anterior communicating artery aneurysms were treated endovascularly (41/64, 64.1%, [52.3–75.8%]), almost all posterior circulation and posterior communicating aneurysms were treated endovascularly (51/53, 96.2%, [91.1–100%]). All proximal intracranial carotid aneurysms were treated endovascularily (80/80, 100%, [95.5–100%]). Factors influencing the choice of treatment modality are the aneurysm location mostly and the aspect ratio. Among the 169 patients harboring 201 UIAs, 135 were female (mean patient age, 57 years [±11 years]).

In 187 procedures there were no deaths, 2 lasting complications, 15 temporary complications, 8 retreatments, and an average 3-night hospital stay (Tables 1 and 2). A total of 91 procedures with flow-diverter stents were performed in 81 patients, treating 100 aneurysms. A total of 21 procedures with stent-assisted coiling were performed in 20 patients, treating 21 aneurysms. A total of 75 procedures with simple or balloon-assisted coiling stents were performed in 60 patients, treating 80 aneurysms. Follow-up data were available for 155/169 (92%) patients. Mean follow-up duration was 21 ± 13 months and retreatment was required in 8/201 (4%, [2–8%]) aneurysms. Notably, no patients required readmission due to clinical complications after discharge.

Table 1.

Location of unruptured intracranial aneurysms and treatments.

Aneurysm location	Endovascularn (%, 95% CI)	Surgeryn (%, 95%CI)	SAC&BACn (95% CI in %)	SACn (95% CI in %)	FDS n (95% CI in %)
Carotido-ophtalmic	67 (33%, 27.2–40.1%)	0 (0%, 0–2.5%)	4 (2.0–12.2%)	0 (0–15.4%)	63 (53.2–71.9%)
Anterior communicating artery	41 (20.5%, 15.4–26.5%)	23 (19.3%, 12.2–26.4%)	29 (26.7–47.1%)	12 (37.7–74.3%)	0 (0–3.7%)
Posterior communicating artery	21 (10.5%, 6.9–15.4%)	2 (1.7%, 0.2–6.0%)	10 (6.9–21.6%)	0 (0–15.4%)	11 (6.3–18.5%)
Basilar artery tip	16 (8%, 5.0–12.5%)	0 (0%, 0-2.5%)	13 (9.8–25.9%)	2 (2.6–28.9%)	1 (0.2–5.4%)
Carotido-cave	13 (6.5%, 3.8–10.7%)	0 (0%, 0–2.5%)	0 (0–4.6%)	0 (0–15.4%)	13 (7.7–21.1%)
Carotid terminus	10 (5%, 2.8–8.9%)	0 (0%, 0–2.5%)	6 (3.5–15.4%)	2 (2.6–28.9%)	2 (0.6–7.0%)
Anterior choroidal artery	9 (4.5%, 2.4–8.2%)	2 (1.7%, 0.2–6.0%)	3 (1.3–10.6%)	0 (0–15.4%)	6 (2.8–12.5%)
Basilar trunk	7 (3.5%, 1.7–7.0%)	0 (0%, 0–2.5%)	3 (1.3–10.6%)	2 (2.6–28.9%)	2 (0.6–7.0%)
Anterior cerebral artery A1	6 (3%, 1.4–6.4%)	0 (0%, 0–2.5%)	5 (2.7–14.0%)	1 (0.9–22.7%)	0 (0–3.7%)
Middle cerebral artery	2 (1%, 0.3–3.6%)	90 (75.6%, 67.9–83.4)	2 (0.7–8.6%)	0 (0–15.4%)	0 (0–3.7%)
Others	9 (4.5%, 2.4–8.2%)	2 (1.7%, 0.2–6.0%)	5 (2.7–14.0%)	2 (2.6–28.9%)	2 (0.6–7.0%)
Total	201 (100%)	119 (100%)	80 (40%)	21 (10%)	100 (50%)

Abbreviations: SC: simple coiling; BAC: balloon-assisted coiling; SAC: stent-assisted coiling; FDS: flow-diverter stent.

Table 2.

Endovascular procedures and outcome by technique.

	SC&BAC	SAC	FDS	Total
Number of procedures performed (n)	75	21	91	187
Mortality (n) % (95% CI)	0 0% (0.0–4.9%)	0 0% (0.0–15.5%)	0 (0%, 0.0–4.1%)	0 0% (0.0–2.0%)
Permanent morbidity (n) % (95% CI)	2 2.7% (0.7–9.2%)	0 0% (0.0–15.5%)	0 (0%, 0.0–4.1%)	2 1.1% (0.3–3.8%)
Transient morbidity (n) % (95% CI)	5 6.7% (2.9–14.7%)	2 9.5% (2.7–28.9%)	8 (9%, 4.5–16.4)	15 8.0% (4.9–12.8%)
Neurological morbidity (n) % (95% CI)	4 5.3% (2.1–12.9%)	2 9.5% (2.7–28.9%)	4 (4.4%, 1.7–10.8%)	10 5.3% (2.9–9.6%)
Ischemic complications (n) % (95% CI)	3 4% (1.4–11.1%)	2 9.5% (2.7–28.9%)	2 (2.2%, 0.6–7.7%)	7 3.7% (1.8–7.5%)
Hemorragic complications (n) % (95% CI)	1 1.3% (0.2–7.2%)	0 0% (0.0–15.5%)	0 (0%, 0.0–4.1%)	1 0.5% (0.1–3.0%)
Ponction site complications(n) % (95% CI)	3 4% (1.4–11.1%)	0 0% (0.0–15.5%)	1 (1.2%, 0.2–6.0%)	4 2.1% (0.8–5.4%)
Other complications (n) % (95% CI)	0 0% (0.0–4.9%)	0 0% (0.0–15.5%)	3 (3.3%, 1.1–9.2%)	3 1.6% (0.5–4.6%)
X-ray: Gy cm2 (mean (SD))	122 (50)	153.5 (49)	133 (66)	127 (56)
Irradiation time min. (mean (SD))	41(17)	48 (17)	28 (15.5)	35 (17)
Hospitalization nights (mean (SD))	3 (1.7)	4 (2.6)	3.8 (2.8)	3 (2)
	SC&BAC	SAC	FDS	Total
Number of aneurysms (n)	80	21	100	201
Aneurysm height mm (mean (SD))	6 (3.9)	4.5 (1.6)	6.5(4)	6.1 (3.8)
Aneurysm diameter mm (mean (SD))	5.8 (4.5)	4.7 (1.6)	6.5 (4)	6 (4)
Neck mm (mean (SD))	3.5 (1.6)	3.8 (1.5)	4 (2.5)	3.8 (2.4)
Dome to neck ratio (mean (SD))	1.7 (0.7)	1 (0.5)	1.7 (0.7)	1.6 (0.7)
Occlusion after EVT median	2 (1–3a)^a	2 (1–3a)^a	A = 95%^bB = 5%^b	n.a.
Occlusion follow-up median	1 (1- 2)^a	1 (1- 1)^a	A = 4%^bB = 3%^bC = 20%^bD = 72%^bn.a. = 1%	n.a.
Retreatment (n)% (95% CI)	45% (2.0–12.2%)	00% (0.0–15.5%)	44% (1.6–9.8%)	84% (2.0–7.7%)
Follow-up months (mean (SD))	18 (9)	18 (12)	23 (16)	21 (13)

Abbreviations: SC: simple coiling; BAC: balloon-assisted coiling; SAC: stent-assisted coiling; FDS: flow-diverter stent; SD: standard deviation.

^aAccording to the Raymond-Roy scale (IQR). IQR: interquartile range.

^bAccording to O'Kelly-Marotta scale.

The patient death after endovascular treatment was observed (0%, [0–2%]). The intervention rate of permanent morbidity was 2/187 (1%, [0.3–3.8%]). The rate of transient morbidity 15/187 (8%, [4.9–12.8%]). The neurological morbidity rate associated with interventions was 10/187 (5.3%, [2.6–9.6%]).

The average length of hospitalization was 3 ± 2 nights and the mean irradiation time was 35 ± 17 min. It was comparable for balloon-assisted coiling/simple coiling and stent-assisted coiling (41 ± 17 min and 48 ± 17 min, respectively), but considerably lower for patients treated with flow-diverter stents (28 min ± 15.5). The average radiation dose delivered to patients was 127 ± 56 Gy·cm² (Table 2).

Outcomes by procedural technique

Aneurysms treated with flow-diverter stents. A total of 91 interventions for the treatment of 100 UIAs were performed (Figure 1(a)-(c)). Among these procedures, no mortality or permanent morbidity was observed (Table 2). Transient morbidity occurred in 8/91 interventions (9%,[4.5–16.4%]) with one-half of patients (n = 4) presenting transient neurological deficits upon awakening only. Among them, one developed contrast-induced encephalopathy, which resolved within 24 h. Two cases of embolic stroke were recorded, with complete neurological recovery within 3 months. Additionally, one patient experienced acute thrombosis of an intracavernous aneurysm, manifesting as facial pain and diplopia, with full resolution of symptoms before the 3-month follow-up.

Figure 1.

(A–C) Lateral angiographic projections of the endovascular treatment of a left ophthalmic carotid aneurysm with a flow-diverter stent. (A) Pre-treatment angiogram. (B) Unsubtracted image showing the implanted device. (C) Six-month follow-up angiogram. (D–F) Anteroposterior angiographic projections of a recurrent anterior communicating artery aneurysm previously treated with surgical clipping 10 years earlier. (D) Pre-treatment angiogram. (E) Unsubtracted image showing the braided stent and a jailed microcatheter within the aneurysm sac. (F) Final post-treatment angiogram. (G–I) Anteroposterior angiographic projections of the endovascular treatment of a left internal carotid artery terminus aneurysm. (G) Pre-treatment angiogram. (H) Coil deployment within the aneurysm sac assisted by a remodeling balloon. (I) Final angiographic result.

Transient morbidity in four other patients was related to non-neurological complications. One patient developed hematomas at the puncture site, successfully managed with simple compression. Two patients with iatrogenic asymptomatic internal cervical carotid artery dissection were treated with a stent, while one patient experienced transient hematuria.

The mean follow-up period was 23 ± 16 months. At the last follow-up, 72% of patients had a complete occlusion of the aneurysm while 20% had an entry remnant, according to the O’Kelly-Marotta scale. Retreatment was necessary in four cases (4%,[1.6–9.8%]) due to a major recurrence. These included two posterior communicating artery aneurysms, one giant carotid-ophthalmic aneurysm, and one dissecting aneurysm of the basilar artery.

Aneurysms treated with stent-assisted coiling. A total of 21 interventions for the treatment of 21 UIAs were performed with stent-assisted coiling (Table 2) (Figure 1(d)–(f)). No mortality or permanent morbidity was observed (0%, [0–15.5%]). Transient morbidity occurred in 2/21 interventions (9.5%, [2.7–28.9%]) due to embolic strokes. However, all neurological symptoms resolved within 3 months. The mean follow-up duration was 18 ± 12 months. Median aneurysm occlusion according to the Raymond-Roy scale was 2[1–3a] at the end of the procedure, improving to 1[1–1] at the last follow-up. No cases required retreatment.

Aneurysms treated with simple- or balloon-assisted coiling. A total of 75 interventions for the treatment of 80 UIAs were performed using simple- or balloon-assisted coiling (Table 2) (Figure 1(g)–(i)).

No mortality was recorded (0%,[0–4.9%]), while permanent morbidity occurred in 2/75 interventions (2.7%, [0.7–9.2%]). These cases were attributed to one hemorrhagic and one ischemic complication. The hemorrhagic complication resulted from microguidewire perforation of the posterior inferior cerebellar artery during the treatment of the aneurysm at its origin. Arterial occlusion was necessary, leading to cerebellar ischemia. The patient subsequently experienced persistent hearing and balance deficits (mRS 2). The ischemic complication was caused by a distal embolic stroke in the territory of the left angular artery, resulting in mild aphasia (mRS 2).

Transient morbidity was observed in 5/75 interventions (6.7%,[2.9–14.7%]) with complications arising from embolic stroke (n = 2), retroperitoneal hematoma (n = 2), one of which required surgical intervention, and femoral artery occlusion (n = 1) requiring surgical recanalization. All patients with transient morbidity were asymptomatic at the 3-month clinical follow-up.

The mean follow-up duration was 18 ± 9 months. Median aneurysm occlusion was 2[1–3a] on the Raymond-Roy scale at the end of the procedure, improving to 1[1–2] at the last follow-up. Retreatment was required in 4/75 cases (5.3%,[2–12.2%]) due to significant recurrence. These included one giant aneurysm, one anterior communicating artery aneurysm, one basilar tip aneurysm, and one wide-neck A1 aneurysm in a patient on lifelong oral anticoagulation therapy.

Discussion

Careful selection between surgical and endovascular modalities, and among endovascular techniques, enabled relatively safe treatment of UIAs in our cohort. We observed no deaths and only 1% permanent neurological morbidity (95% CI 0.3–3.8%) and 4% retreatment rate (95% CI 2–8%). Importantly, other large series have reported mortality or permanent deficit rates up to 3%. Our results are consistent with published series^8,9 and suggest that, in carefully selected patients, endovascular treatment can be performed with low rates of major complications. It is important to note that these favorable results reflect strong case selection, particularly the systematic referral of MCA aneurysms to surgery, and may not generalize to all centers or aneurysm types.

Results align with the findings of Algra et al.⁹ who performed a meta-analysis of 114 studies involving over 100,000 patients and reported a 30-day complication rate of 4.96%, including a mortality rate of 0.3%, ischemic events in 2.8%, and hemorrhagic events in 0.9% . Notably, despite the anticipated higher risk associated with more complex endovascular techniques, such as stent-assisted coiling and flow-diverter stents, our data revealed no significant increase in morbidity or mortality compared to simple- or balloon-assisted coiling.

With regard to flow-diverter stents, our series reported no mortality or permanent morbidity. This mirrors the low but non-zero risks reported in large meta-analyses such as Bhatia et al.,⁸ which assessed 901 PED Flex procedures and found a mortality rate of 0.8%, a 0.6% rate of major ischemic stroke, and a 1.2% rate of intracranial hemorrhage, culminating in an overall complication rate of 9.8%. Similarly, Zhou et al.¹⁰ reported a mortality rate of 2.8% and a permanent morbidity rate of 3.7% across more than 3000 patients treated with flow-diverter stents. In our cohort, only two minor strokes (2.2%) and six other complications (6.6%) were observed across 91 procedures. Of particular note, none of our flow-diverter-treated patients experienced major complications.

The use of stent-assisted coiling has traditionally raised concerns due to the need for dual antiplatelet therapy and the theoretical risk of thromboembolic and hemorragic events.^11,12 Nevertheless, our data showed no mortality or permanent morbidity in this subgroup. Two patients (9.5%) experienced transient ischemic complications with complete recovery within 3 months. These results echo those of Ji et al.¹³ who found that stent-assisted coiling may be protective against neurological complications in selected patients.

However, the literature on this topic remains heterogeneous. Meta-analyses by Cagnazzo¹⁴ and Akram¹⁵ reported complication rates of 5–7.4%, with ischemic events in 2.4–2.6%, in-stent thrombosis in 1.5–3.5%, and overall morbidity around 1.5%. A key limitation of these studies is the inclusion of ruptured aneurysms, which are known to carry substantially higher peri-procedural risks. Indeed, Bechan et al.¹⁶ demonstrated that the presence of subarachnoid hemorrhage increases the risk of thromboembolic events, thereby confounding comparisons with series limited to unruptured aneurysms.

Our findings regarding simple- and balloon-assisted coiling are also consistent with the ATENA study,¹⁷ which evaluated 739 unruptured aneurysms across 27 centers and reported an overall complication rate of 15.4%, including embolic stroke in 7.1% and procedural rupture in 2.6%, with a mortality rate of 0.9%. In our series, no mortality was recorded in this subgroup and permanent morbidity was limited to 2.5%. In our study, embolic stroke occurred in 4% of cases for this intervention group, but only one patient experienced a lasting neurological deficit. Notably, no cases of aneurysm rupture occurred during the procedures; the single hemorrhagic complication resulted from perforation of an artery during microcatheter navigation.

Importantly, when comparing across treatment modalities, we observed no notable difference in permanent morbidity or retreatment rates.

These favorable outcomes may be partly attributed to the multidisciplinary approach adopted at our center for patient selection. However, such an algorithm is specific to our center, tailored to individual patient characteristics, and therefore not directly generalizable to other institutions or settings (Table 3). It also represents a simplified depiction of our decision-making process, from which we may deliberately deviate in specific cases when clinically justified.

Table 3.

Decision-making algorithm for unruptured intracranial aneurysms.

Identify aneurysm location

Anterior circulation

Middle cerebral artery bifurcation → Microsurgical clipping!

Pericallosal bifurcation → Microsurgical clipping vs Endovascular treatment

Proximal ICA side-wall → Endovascular treatment

Carotid terminus→ Endovascular treatment

Anterior communicating artery → Primarily coiling, clipping or stenting when branch preservation is challenging

Posterior communicating artery or anterior choroidal artery small aneurysms → Primarily coiling or stenting, clipping when branch preservation is challenging

Posterior circulation

Basilar artery → Endovascular treatment

Posterior inferior cerebellar artery →Primarily coiling, clipping when branch preservation is challenging

Assess aneurysm morphology

Narrow neck → Simple or balloon-assisted coiling

Wide neck or low dome-to-neck ratio → Flow diversion or clipping or stent-assisted coiling, depending on location

Evaluate risk–benefit balance

If procedural risk > expected benefit → Surveillance

The distribution of aneurysm locations in our cohort is broadly consistent with that reported in the international literature and with data previously published by our group. In the large pooled analysis conducted by the International Stroke Genetics Consortium, the most frequent sites were the anterior communicating artery (26.7%), the middle cerebral artery (25.9%), and the posterior communicating artery (14.7%).^18,19 In contrast, our endovascular series showed a predominance of carotido-ophthalmic aneurysms (33%), followed by the anterior communicating artery (20.5%) and the posterior communicating artery (10.5%). This pattern likely reflects a therapeutic strategy guided by a multidisciplinary approach in which both aneurysm location and its morphological characteristics play a crucial role in selecting the treatment modality.

In particular, complex middle cerebral artery aneurysms, commonly associated with higher endovascular-related risk or recurrence, were typically referred for surgical clipping following multidisciplinary team discussion. This collaborative process between interventional neuroradiologists and neurosurgeons ensures tailored therapeutic strategies based on aneurysm morphology, location, and patient-specific factors. Our protocol helps early-career operators by making expert reasoning explicit and reproducible: (i) mandatory multidisciplinary team review with a documented indication and alternatives (including surveillance), (ii) locally audited absolute risks with 95% CIs to calibrate consent and expectations, (iii) non-prescriptive selection tendencies that map common aneurysm archetypes to typical techniques, (iv) a standardized peri-procedural pathway (planning checks, intra-op safety steps, radiation monitoring, follow-up), and (v) clear supervision/escalation criteria with routine debriefs. Together, these elements reduce cognitive load, enhance safety, and accelerate deliberate practice toward independent decision-making.

Our study has several limitations. First, the relatively small number of patients. Second, its single-center design, which limits its generalizability and, third, the non-randomized allocation of treatment.

Teaching points

In a multidisciplinary, selection-driven practice, endovascular treatment of carefully chosen UIAs can be performed with very low major complications (no deaths, 1% permanent morbidity) and modest retreatment needs (4% over 5 years). Technique selection should be individualized, primarily by aneurysm location and morphology and patient factors, rather than dictated by a rigid algorithm; in our cohort, flow diversion and stent-assisted coiling were not associated with higher permanent morbidity than simple/balloon-assisted coiling. For informed consent, patients should receive absolute, locally audited risks (with 95% CIs) alongside literature benchmarks, including the uncertainty around retreatment and morbidity. When estimated procedural risk exceeds expected benefit, surveillance remains appropriate. Ongoing work will formalize this approach into probabilistic decision support using real-world data, with external, prospective validation (ideally in pragmatic comparative studies).

Conclusions

This study shows the clinical and anatomical results associated with tailored endovascular treatment of carefully selected UIAs at our center. At our center, endovascular treatment of UIAs resulted in no deaths, about 1% permanent morbidity, and 4% retreatment over a mean follow-up of nearly 2 years. These outcomes reflect our multidisciplinary case selection and local practice. By reporting them in clear terms, we aim to support informed patient decision-making and maintain transparent benchmarking of our performance. Continued practice and outcome monitoring will be essential to maintain optimal practices and further improve patient outcomes in this evolving field.

Footnotes

Acknowledgments

The authors thank Rosemary Sudan for her careful English language editing of the manuscript.

ORCID iDs

Gianmarco Bernava

Abiram Sandralegar

Jeremy Hofmeister

Philippe Reymond

Ethical approval

This study was deemed to fall outside the scope of Swiss human research legislation and consequently did not require approval by a local ethics committee.

Contributors’ statement

Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work; revising it critically for important intellectual content; final approval of the version to be published; and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: all authors.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The @neurIST project was supported by the 6th framework program of the European Commission (FP6-IST-2004-027703). This study was also supported by grants from the Swiss SystemsX.ch initiative, evaluated by the Swiss National Science Foundation [to P.B.], from the Fondation Privée des Hôpitaux Universitaires de Genève [to P.B.] and from the EU Horizon Europe R&I program (GEMINI no. 101136438). The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Declaration of conflicting interest

P.M. is a consultant for Medtronic and Stryker. All other authors declare no conflicting interests.

Data sharing statement

All data are available upon request to the corresponding author.

References

Etminan

Brown

Beseoglu

, et al. The unruptured intracranial aneurysm treatment score: a multidisciplinary consensus. Neurology 2015; 85: 881–889.

Backes

Vergouwen

MDI

Tiel Groenestege

, et al. PHASES score for prediction of intracranial aneurysm growth. Stroke 2015; 46: 1221–1226.

Pierot

Wakhloo

. Endovascular treatment of intracranial aneurysms: current status. Stroke 2013; 44: 2046–2054.

Lauzier

Huguenard

Srienc

, et al. A review of technological innovations leading to modern endovascular brain aneurysm treatment. Front Neurol 2023; 14: 1156887.

Delucchi

Spinner

Scutari

, et al. Bayesian network analysis reveals the interplay of intracranial aneurysm rupture risk factors. Comput Biol Med 2022: 147. doi:10.1016/J.COMPBIOMED.2022.105740

Roy

Milot

Raymond

. Endovascular treatment of unruptured aneurysms. Stroke 2001; 32: 1998–2004.

O'kelly

Krings

Fiorella

, et al. A novel grading scale for the angiographic assessment of intracranial aneurysms treated using flow diverting stents. Interv Neuroradiol 2010; 16: 133–137.

Bhatia

Kortman

Orru

, et al. Periprocedural complications of second-generation flow diverter treatment using pipeline flex for unruptured intracranial aneurysms: a systematic review and meta-analysis. J Neurointerv Surg 2019; 11: 817–824.

Algra

Lindgren

Vergouwen

MDI

, et al. Procedural clinical complications, case-fatality risks, and risk factors in endovascular and neurosurgical treatment of unruptured intracranial aneurysms: a systematic review and meta-analysis. JAMA Neurol 2019; 76: 282–293.

10.

Zhou

Yin

, et al. Complications associated with the use of flow-diverting devices for cerebral aneurysms: a systematic review and meta-analysis. Neurosurg Focus 2017; 42. doi:10.3171/2017.3.FOCUS16450

11.

Ortiz-Giraldo

Vera

Catalá

, et al. Angiographic outcomes of embolization in patients with intracranial aneurysms with coil-assisted laser cut stent versus braided stents. Interv Neuroradiol 2023; 31: 482.

12.

Holden

May

Robbins

, et al. Multicenter comparison of antiplatelet treatment strategies for urgent/emergent neuroendovascular stenting. Interv Neuroradiol 2023; 31: 626.

13.

Liu

, et al. Risk score for neurological complications after endovascular treatment of unruptured intracranial aneurysms. Stroke 2016; 47: 971–978.

14.

Cagnazzo

Cappucci

Lefevre

, et al. Treatment of intracranial aneurysms with self-expandable braided stents: a systematic review and meta-analysis. Am J Neuroradiol 2018; 39: 2064–2069.

15.

Akram

Ahmed

Nadeem

, et al. Safety and efficacy of the neuroform atlas stent for treatment of intracranial aneurysms: a systematic review, meta-analysis, and meta-regression. Am J Neuroradiol 2025; 46: 1120–1129.

16.

Bechan

Sprengers

Majoie

, et al. Stent-assisted coil embolization of intracranial aneurysms: complications in acutely ruptured versus unruptured aneurysms. Am J Neuroradiol 2016; 37: 502–507.

17.

Pierot

Spelle

Vitry

. Immediate clinical outcome of patients harboring unruptured intracranial aneurysms treated by endovascular approach: results of the ATENA study. Stroke 2008; 39: 2497–2504.

18.

Morel

Hostettler

Spinner

, et al. Intracranial aneurysm classifier using phenotypic factors: an international pooled analysis. J Pers Med 2022; 12: 1410.

19.

Bakker

Kanning

Abraham

, et al. Genetic risk score for intracranial aneurysms: prediction of subarachnoid hemorrhage and role in clinical heterogeneity. Stroke 2023; 54: 810–818.

Endovascular treatment of unruptured intracranial aneurysms at a single center: Outcomes,selection strategy,and transparent communication for patient decision-making

Abstract

Background

Objective

Methods

Results

Conclusions

Keywords

Introduction

Methods

Statistical analysis

Results

Outcomes by procedural technique

Discussion

Teaching points

Conclusions

Footnotes

Acknowledgments

ORCID iDs

Ethical approval

Contributors’ statement

Funding

Declaration of conflicting interest

Data sharing statement

References